Literature DB >> 25678239

Detection of Trypanosoma cruzi DNA in blood by PCR is associated with Chagas cardiomyopathy and disease severity.

E C Sabino1, A L Ribeiro, T H Lee, C L Oliveira, A B Carneiro-Proietti, A P Antunes, M M Menezes, B M Ianni, V M Salemi, L Nastari, F Fernandes, V Sachdev, D M Carrick, X Deng, D Wright, T T Gonçalez, E L Murphy, B Custer, M P Busch.   

Abstract

BACKGROUND: The significance of detection of Trypanosoma cruzi DNA in blood of antibody-positive patients for risk of development of Chagas heart disease is not well established. The objective of this study was to compare detection of T. cruzi DNA with known clinical and laboratory markers of Chagas cardiomyopathy (CC) severity.
METHODS: This is a case-control study nested within a retrospective cohort developed in Brazil to understand the natural history of Chagas disease. The study enrolled 499 T. cruzi seropositive blood donors (SP-BD) and 488 frequency matched seronegative control donors (SN-BD) who had donated between 1996 and 2002, and 101 patients with clinically diagnosed CC. In 2008-2010 all enrolled subjects underwent a health questionnaire, medical examination, electrocardiograms and echocardiograms and polymerase chain reaction (PCR) analyses. A blinded panel of three cardiologists adjudicated the outcome of CC. Trypanosoma cruzi kinetoplast minicircle sequences were amplified by real-time PCR using an assay with a sensitivity of one parasite per 20 mL of blood. All testing was performed on coded samples.
RESULTS: Rates of PCR detection of T. cruzi DNA were significantly (P = 0.003) higher in CC patients and SP-BD diagnosed with CC (79/105 [75.2 %]) compared with SP-BD without CC (143/279 [51.3%]). The presence of parasitaemia was significantly associated with known markers of disease progression such as QRS and QT interval duration, lower left ventricular ejection fraction, higher left ventricular index mass, and elevated troponin and NTpro-BNP levels.
CONCLUSION: Trypanosoma cruzi PCR positivity is associated with presence and severity of cardiomyopathy, suggesting a direct role of parasite persistence in disease pathogenesis.
© 2015 The Authors. European Journal of Heart Failure © 2015 European Society of Cardiology.

Entities:  

Keywords:  PCR; Trypanosoma cruzi; cardiomyopathy

Mesh:

Substances:

Year:  2015        PMID: 25678239      PMCID: PMC5665686          DOI: 10.1002/ejhf.220

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  29 in total

Review 1.  Chagas heart disease: report on recent developments.

Authors:  Fabiana S Machado; Linda A Jelicks; Louis V Kirchhoff; Jamshid Shirani; Fnu Nagajyothi; Shankar Mukherjee; Randin Nelson; Christina M Coyle; David C Spray; Antonio C Campos de Carvalho; Fangxia Guan; Cibele M Prado; Michael P Lisanti; Louis M Weiss; Susan P Montgomery; Herbert B Tanowitz
Journal:  Cardiol Rev       Date:  2012 Mar-Apr       Impact factor: 2.644

2.  Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT).

Authors:  Jose Antonio Marin-Neto; Anis Rassi; Carlos A Morillo; Alvaro Avezum; Stuart J Connolly; Sergio Sosa-Estani; Fernando Rosas; Salim Yusuf
Journal:  Am Heart J       Date:  2008-07       Impact factor: 4.749

3.  Parasite persistence correlates with disease severity and localization in chronic Chagas' disease.

Authors:  L Zhang; R L Tarleton
Journal:  J Infect Dis       Date:  1999-08       Impact factor: 5.226

Review 4.  Chagas disease.

Authors:  Anis Rassi; Anis Rassi; José Antonio Marin-Neto
Journal:  Lancet       Date:  2010-04-17       Impact factor: 79.321

5.  Evidence of Chagas disease in seronegative Brazilian patients with megaesophagus.

Authors:  Angelica M Batista; Camila Aguiar; Eros A Almeida; Maria E Guariento; Jamiro S Wanderley; Sandra C B Costa
Journal:  Int J Infect Dis       Date:  2010-09-15       Impact factor: 3.623

6.  Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial.

Authors:  Rodolfo Viotti; Carlos Vigliano; Bruno Lococo; Graciela Bertocchi; Marcos Petti; María Gabriela Alvarez; Miriam Postan; Alejandro Armenti
Journal:  Ann Intern Med       Date:  2006-05-16       Impact factor: 25.391

7.  Chronic American trypanosomiasis: parasite persistence in endomyocardial biopsies is associated with high-grade myocarditis.

Authors:  L A Benvenuti; A Roggério; H F G Freitas; A J Mansur; A Fiorelli; M L Higuchi
Journal:  Ann Trop Med Parasitol       Date:  2008-09

8.  Trypanosoma cruzi DNA in cardiac lesions of Argentinean patients with end-stage chronic chagas heart disease.

Authors:  Alejandro G Schijman; Carlos A Vigliano; Rodolfo J Viotti; Juan M Burgos; Silvia Brandariz; Bruno E Lococo; Maria I Leze; Hector A Armenti; Mariano J Levin
Journal:  Am J Trop Med Hyg       Date:  2004-02       Impact factor: 2.345

9.  Ten-year incidence of Chagas cardiomyopathy among asymptomatic Trypanosoma cruzi-seropositive former blood donors.

Authors:  Ester C Sabino; Antonio L Ribeiro; Vera M C Salemi; Claudia Di Lorenzo Oliveira; Andre P Antunes; Marcia M Menezes; Barbara M Ianni; Luciano Nastari; Fabio Fernandes; Giuseppina M Patavino; Vandana Sachdev; Ligia Capuani; Cesar de Almeida-Neto; Danielle M Carrick; David Wright; Katherine Kavounis; Thelma T Goncalez; Anna Barbara Carneiro-Proietti; Brian Custer; Michael P Busch; Edward L Murphy
Journal:  Circulation       Date:  2013-02-07       Impact factor: 29.690

10.  Genome wide association study (GWAS) of Chagas cardiomyopathy in Trypanosoma cruzi seropositive subjects.

Authors:  Xutao Deng; Ester C Sabino; Edecio Cunha-Neto; Antonio L Ribeiro; Barbara Ianni; Charles Mady; Michael P Busch; Mark Seielstad
Journal:  PLoS One       Date:  2013-11-20       Impact factor: 3.240

View more
  11 in total

1.  Inflammatory and cardiac biomarkers are differentially expressed in clinical stages of Chagas disease.

Authors:  S M Keating; X Deng; F Fernandes; E Cunha-Neto; A L Ribeiro; B Adesina; A I Beyer; P Contestable; B Custer; M P Busch; E C Sabino
Journal:  Int J Cardiol       Date:  2015-07-12       Impact factor: 4.164

2.  Blood Gene Signatures of Chagas Cardiomyopathy With or Without Ventricular Dysfunction.

Authors:  Ludmila Rodrigues Pinto Ferreira; Frederico Moraes Ferreira; Helder Imoto Nakaya; Xutao Deng; Darlan da Silva Cândido; Lea Campos de Oliveira; Jean-Noel Billaud; Marion C Lanteri; Vagner Oliveira-Carvalho Rigaud; Mark Seielstad; Jorge Kalil; Fabio Fernandes; Antonio Luiz P Ribeiro; Ester Cerdeira Sabino; Edecio Cunha-Neto
Journal:  J Infect Dis       Date:  2017-02-01       Impact factor: 5.226

3.  Amiodarone and Trypanosoma cruzi parasitemia in patients with Chagas disease.

Authors:  Andre A L Carmo; Manoel O C Rocha; Jose L P Silva; Barbara M Ianni; Fabio Fernandes; Ester C Sabino; Antonio L P Ribeiro
Journal:  Int J Cardiol       Date:  2015-04-11       Impact factor: 4.164

Review 4.  Developments in the management of Chagas cardiomyopathy.

Authors:  Herbert B Tanowitz; Fabiana S Machado; David C Spray; Joel M Friedman; Oren S Weiss; Jose N Lora; Jyothi Nagajyothi; Diego N Moraes; Nisha Jain Garg; Maria Carmo P Nunes; Antonio Luiz P Ribeiro
Journal:  Expert Rev Cardiovasc Ther       Date:  2015-10-23

5.  IL-17A, a possible biomarker for the evaluation of treatment response in Trypanosoma cruzi infected children: A 12-months follow-up study in Bolivia.

Authors:  Clara Vásquez Velásquez; Graciela Russomando; Emilio E Espínola; Zunilda Sanchez; Kota Mochizuki; Yelin Roca; Jimmy Revollo; Angelica Guzman; Benjamín Quiroga; Susana Rios Morgan; Roberto Vargas Ortiz; Alberto Zambrana Ortega; Eida Espinoza; Juan Eiki Nishizawa; Mohamed Gomaa Kamel; Mihoko Kikuchi; Shusaku Mizukami; Kesara Na-Bangchang; Nguyen Tien Huy; Kenji Hirayama
Journal:  PLoS Negl Trop Dis       Date:  2019-09-25

6.  A therapeutic vaccine prototype induces protective immunity and reduces cardiac fibrosis in a mouse model of chronic Trypanosoma cruzi infection.

Authors:  Meagan A Barry; Leroy Versteeg; Qian Wang; Jeroen Pollet; Bin Zhan; Fabian Gusovsky; Maria Elena Bottazzi; Peter J Hotez; Kathryn M Jones
Journal:  PLoS Negl Trop Dis       Date:  2019-05-30

7.  Vaccine-linked chemotherapy induces IL-17 production and reduces cardiac pathology during acute Trypanosoma cruzi infection.

Authors:  Julio V Cruz-Chan; Liliana E Villanueva-Lizama; Leroy Versteeg; Ashish Damania; Maria José Villar; Cristina González-López; Brian Keegan; Jeroen Pollet; Fabian Gusovsky; Peter J Hotez; Maria Elena Bottazzi; Kathryn M Jones
Journal:  Sci Rep       Date:  2021-02-05       Impact factor: 4.379

8.  Beneficial effects of benznidazole in Chagas disease: NIH SaMi-Trop cohort study.

Authors:  Clareci Silva Cardoso; Antonio Luiz P Ribeiro; Claudia Di Lorenzo Oliveira; Lea Campos Oliveira; Ariela Mota Ferreira; Ana Luiza Bierrenbach; José Luiz Padilha Silva; Enrico Antonio Colosimo; João Eduardo Ferreira; Tzong-Hae Lee; Michael P Busch; Arthur Lawrence Reingold; Ester Cerdeira Sabino
Journal:  PLoS Negl Trop Dis       Date:  2018-11-01

9.  A Specific IL6 Polymorphic Genotype Modulates the Risk of Trypanosoma cruzi Parasitemia While IL18, IL17A, and IL1B Variant Profiles and HIV Infection Protect Against Cardiomyopathy in Chagas Disease.

Authors:  Alexandra Gomes Dos Santos; Elieser Hitoshi Watanabe; Daiane Tomomi Ferreira; Jamille Oliveira; Érika Shimoda Nakanishi; Claudia Silva Oliveira; Edimar Bocchi; Cristina Terra Gallafrio Novaes; Fatima Cruz; Noemia Barbosa Carvalho; Paula Keiko Sato; Edite Hatsumi Yamashiro-Kanashiro; Alessandra Pontillo; Vera Lucia Teixeira de Freitas; Luiz Fernando Onuchic; Maria Aparecida Shikanai-Yasuda
Journal:  Front Immunol       Date:  2020-10-22       Impact factor: 7.561

10.  Declining antibody levels to Trypanosoma cruzi correlate with polymerase chain reaction positivity and electrocardiographic changes in a retrospective cohort of untreated Brazilian blood donors.

Authors:  Lewis F Buss; Léa Campos de Oliveira-da Silva; Carlos H V Moreira; Erika R Manuli; Flavia C Sales; Ingra Morales; Clara Di Germanio; Cesar de Almeida-Neto; Sonia Bakkour; Paul Constable; Marcelo M Pinto-Filho; Antonio L Ribeiro; Michael Busch; Ester C Sabino
Journal:  PLoS Negl Trop Dis       Date:  2020-10-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.